Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

MOUNJARO prices in the UK could double as the manufacturer will next month hike the rate it charges pharmacies for the fat ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

Mounjaro prices are to double on September 1 says the pharmaceutical giant that makes the weight loss jab. The 15mg pen is expected to cost ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.